Consider reduction of dialysis work on On-line HDF implementation ~ From timing of drug administration ~

Consider reduction of dialysis work on On-line HDF implementation ~ From timing of drug administration ~ - HDF TD study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000026361

Enrollment

Registered

2017-06-01

Start date

2017-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients in need of treatment for renal anemia due to ESA administration in patients under On-line HDF treatment

Interventions

Epoetin beta (genetical recombination) group Change ESA administration from On-line HDF end to on-line HDF enforcement (1 to 2 hours after start). Darbepoietin alpha (genetical recombination) group

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) The age at the time of acquiring consent is between 20 and 85 years old (2) Renal anemia treatment by ESA administration is under way (3) More than 3 months have passed since On-line HDF implementation (4) ESA has been administered to achieve an anemia improvement target (Hb value of 10 g / dl or more, less than 12 g / dl) continuously for 3 months or more (5) Patient consent was obtained from the patient himself / herself for this research participation

Exclusion criteria

Exclusion criteria: 1) Patients with anemia due to factors other than renal anemia (2) Patients with hypersensitivity to epoetin beta (genetical recombination), darbepoietin alpha (genetical recombination), epoetin beta pegol (genetical recombination) (3) Patients with malignant tumors (4) Pregnant women or patients who may be pregnant, breastfeeding, or who desire pregnancy during research participation (women only) (5) Other Research Responsibilities (In charge) Patients judged by doctors as inappropriate for this study

Design outcomes

Primary

Measure	Time frame
Administration of 30 (30 each) between the three groups of epoetin beta (genetical recombination) group, darbepoietin alpha (genetical recombination) group and epoetin beta pegol (gene recombination) group was administered on-line from the end of on-line HDF Change the target hemoglobin (Hb) maintenance rate and ESA dose during the HDF execution (1 to 2 hours after the start) to examine whether there is an influence due to the change of the ESA administration timing.	—

Measure

Time frame

Administration of 30 (30 each) between the three groups of epoetin beta (genetical recombination) group, darbepoietin alpha (genetical recombination) group and epoetin beta pegol (gene recombination) group was administered on-line from the end of on-line HDF Change the target hemoglobin (Hb) maintenance rate and ESA dose during the HDF execution (1 to 2 hours after the start) to examine whether there is an influence due to the change of the ESA administration timing.

—

Countries

Japan

Contacts

Public ContactHiroshi Sakurai

Kaikoukai Medical Foundation Dialysis Medical Division

hrsakurai@kaikou.or.jp052-363-7211

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026